WANECAM 2
Kick-off
Read our newsletter
Our collaborators
Our financial partner
Our partners
WANECAM is the West African Network for Clinical Trials of Antimalarial drugs. This network is being supported by grants from the European & Developing Countries Clinical Trials Partnership (EDCTP).
The WANECAM 2 project aims to accelerate the development of the Ganaplacide/lumefantrine combination for the treatment of uncomplicated malaria by conducting clinical trials in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger. Moreover, and very importantly, the project includes activities around capacity building (e.g. training and infrastructure development) to improve the capabilities in West African countries to develop new antimalarial drugs. The aim is to advance the development of a much-needed new antimalarial therapy while strengthening clinical trial development capabilities in Africa.
Malaria continues to be a major health problem, particularly in sub-Saharan Africa where 92% of the 219 million new cases and 93% of the 435 000 deaths from malaria were recorded in 2017 according to the WHO 2018 report. The disease is responsible for an unacceptable number of hospital admissions and outpatient visits and greatly contributes to poverty in most of sub-Saharan Africa. With the development of artemisinin resistance in Southeast Asia, and the risk of expansion to the sub-Saharan Africa region, there is an urgent need for a non-artemisinin-based drug combination for malaria treatment…..
Our financial partner
Our partners
